IRIS Accounts Production v25.2.0.378 12267717 Board of Directors 31.12.24 1.1.24 31.12.24 31.12.24 Medium entities These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. true true true false true true false false false false false false false false false false true false Ordinary 0 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh122677172023-12-31122677172024-12-31122677172024-01-012024-12-31122677172022-12-31122677172023-01-012023-12-31122677172023-12-3112267717ns15:EnglandWales2024-01-012024-12-3112267717ns14:PoundSterling2024-01-012024-12-3112267717ns10:Director12024-01-012024-12-3112267717ns10:Consolidated2024-12-3112267717ns10:ConsolidatedGroupCompanyAccounts2024-01-012024-12-3112267717ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3112267717ns10:Consolidatedns10:MediumEntities2024-01-012024-12-3112267717ns10:Consolidatedns10:Audited2024-01-012024-12-3112267717ns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-01-012024-12-3112267717ns10:Medium-sizedCompaniesRegimeForAccounts2024-01-012024-12-3112267717ns10:Consolidated2024-01-012024-12-3112267717ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForDirectorsReport2024-01-012024-12-3112267717ns10:Consolidatedns10:Medium-sizedCompaniesRegimeForAccounts2024-01-012024-12-3112267717ns10:FullAccounts2024-01-012024-12-3112267717ns5:Subsidiary12024-01-012024-12-3112267717ns5:Subsidiary22024-01-012024-12-3112267717ns5:Subsidiary32024-01-012024-12-3112267717ns5:Subsidiary42024-01-012024-12-3112267717ns5:Subsidiary52024-01-012024-12-3112267717ns5:Subsidiary62024-01-012024-12-3112267717ns5:Associate12024-01-012024-12-311226771712024-01-012024-12-3112267717ns10:OrdinaryShareClass12024-01-012024-12-3112267717ns10:Director22024-01-012024-12-3112267717ns10:Director32024-01-012024-12-3112267717ns10:RegisteredOffice2024-01-012024-12-3112267717ns10:Consolidated2023-01-012023-12-3112267717ns5:ShareCapital2024-12-3112267717ns5:ShareCapital2023-12-3112267717ns5:FurtherSpecificReserve1ComponentTotalEquity2024-12-3112267717ns5:FurtherSpecificReserve1ComponentTotalEquity2023-12-3112267717ns5:ShareCapital2022-12-3112267717ns5:RetainedEarningsAccumulatedLosses2022-12-3112267717ns5:FurtherSpecificReserve1ComponentTotalEquity2022-12-3112267717ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-3112267717ns5:FurtherSpecificReserve1ComponentTotalEquity2023-01-012023-12-3112267717ns5:RetainedEarningsAccumulatedLosses2023-12-3112267717ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-3112267717ns5:FurtherSpecificReserve1ComponentTotalEquity2024-01-012024-12-3112267717ns5:RetainedEarningsAccumulatedLosses2024-12-3112267717ns5:NetGoodwill2024-01-012024-12-3112267717ns5:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-3112267717ns5:PatentsTrademarksLicencesConcessionsSimilar2024-01-012024-12-3112267717ns5:LandBuildingsns5:OwnedOrFreeholdAssets2024-01-012024-12-3112267717ns5:LandBuildingsns5:ShortLeaseholdAssets2024-01-012024-12-3112267717ns5:PlantMachinery2024-01-012024-12-3112267717ns5:FurnitureFittings2024-01-012024-12-3112267717ns5:MotorVehicles2024-01-012024-12-3112267717ns5:ComputerEquipment2024-01-012024-12-3112267717ns5:CostValuation2023-12-31122677171ns5:Subsidiary12024-01-012024-12-3112267717ns5:Subsidiary12024-12-3112267717ns5:Subsidiary12023-12-3112267717ns5:Subsidiary12023-01-012023-12-3112267717ns5:Subsidiary232024-01-012024-12-3112267717ns5:Subsidiary22024-12-3112267717ns5:Subsidiary22023-12-3112267717ns5:Subsidiary22023-01-012023-12-31122677175ns5:Subsidiary32024-01-012024-12-3112267717ns5:Subsidiary32024-12-3112267717ns5:Subsidiary32023-12-3112267717ns5:Subsidiary32023-01-012023-12-31122677177ns5:Subsidiary42024-01-012024-12-3112267717ns5:Subsidiary42024-12-3112267717ns5:Subsidiary42023-12-3112267717ns5:Subsidiary42023-01-012023-12-3112267717ns5:Subsidiary592024-01-012024-12-3112267717ns5:Subsidiary52024-12-3112267717ns5:Subsidiary52023-12-3112267717ns5:Subsidiary52023-01-012023-12-3112267717ns5:Subsidiary6112024-01-012024-12-3112267717ns5:Subsidiary62024-12-3112267717ns5:Subsidiary62023-12-3112267717ns5:Subsidiary62023-01-012023-12-3112267717ns5:Associate112024-01-012024-12-3112267717ns5:Associate12024-12-3112267717ns5:Associate12023-12-3112267717ns5:Associate12023-01-012023-12-3112267717ns5:CurrentFinancialInstruments2024-12-3112267717ns5:CurrentFinancialInstruments2023-12-3112267717ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3112267717ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3112267717ns10:OrdinaryShareClass12024-12-3112267717ns5:RetainedEarningsAccumulatedLosses2023-12-3112267717ns5:FurtherSpecificReserve1ComponentTotalEquity2023-12-31
REGISTERED NUMBER: 12267717 (England and Wales)















Group Strategic Report, Report of the Directors and

Consolidated Financial Statements for the Year Ended 31 December 2024

for

Alpha-Cure Group Limited

Alpha-Cure Group Limited (Registered number: 12267717)






Contents of the Consolidated Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Group Strategic Report 2

Report of the Directors 4

Report of the Independent Auditors 6

Consolidated Income Statement 10

Consolidated Other Comprehensive Income 11

Consolidated Balance Sheet 12

Company Balance Sheet 14

Consolidated Statement of Changes in Equity 16

Company Statement of Changes in Equity 17

Consolidated Cash Flow Statement 18

Notes to the Consolidated Cash Flow Statement 19

Notes to the Consolidated Financial Statements 21


Alpha-Cure Group Limited

Company Information
for the Year Ended 31 December 2024







DIRECTORS: S P Atherstone
S Haines
M A Slater





REGISTERED OFFICE: Leonard House
Unit 2 Great Central Way
Woodford Halse
Daventry
Northamptonshire
NN11 3PZ





REGISTERED NUMBER: 12267717 (England and Wales)





AUDITORS: CED Accountancy Services Limited
Statutory Auditors
Chartered Accountants
1 Lucas Bridge Business Park
1 Old Greens Norton Road
Towcester
Northamptonshire
NN12 8AX

Alpha-Cure Group Limited (Registered number: 12267717)

Group Strategic Report
for the Year Ended 31 December 2024

The directors present their strategic report of the company and the group for the year ended 31 December 2024.

BUSINESS OVERVIEW
Alpha-Cure is recognised globally for delivering the highest quality UV lamp technology directly to end-users, and working in partnership with leading UV system manufacturers around the world. Established in 1996 Alpha-Cure is a specialist manufacturer of ultraviolet (UV) curing and metal halide lamps.

Our mission is to be the leading manufacturer and supplier within the UV industry and to grow our worldwide reach. We will achieve our mission by continuing to develop our portfolio of UV products focused on technology innovations whilst delivering excellent customer service and ensuring employee satisfaction.

The continuing development of new products and innovative manufacturing processes, along with continuing improvements made to the usable lives of existing products, have significantly contributed to the group's growth and ensures that the Alpha-Cure Group remains at the forefront of the UV and Metal Halide lamp industry.

With our knowledge of the industry and focussed direction of management, we feel confident that the group will continue to do well, despite the current challenges to the world economy.

BUSINESS MODEL

We operate a vertically integrated model, managing product design, manufacturing and distribution, through our worldwide network in Europe, Asia, North America and Australia Asia.
Revenue is generated through direct sales and developing these long-term relationships.

STRATEGY

Our strategic priorities for the next three years include:
Market Expansion: Entering new niche uses for the products and entering new regional markets across Europe, North America.
Innovation: Investing in R&D to develop to expand the markets in which our products operate The Company is continually developing its manufacturing processes and product range so as to keep up with ever changing demand from customers and machinery manufacturers.
Sustainability and the environment: We will always work towards ensuring that our company reduces the impact on the environment when operating our business management system and seek continual improvement

PRINCIPAL RISKS AND UNCERTAINTIES
Regulatory Risk: Changes in government regulation could impact demand.
Supply Chain Disruption: Global economic trade changes between countries.
Innovation: Changing demand from customers and machinery manufacturers.
Each risk is monitored by the management and mitigated through supplier diversification, regular reviews and proactive regulatory engagement.

FINANCIAL KEY PERFORMANCE INDICATORS
The Directors have monitored the progress of the overall group strategy and the individual strategic elements by reference to certain key performance indicators.

Turnover: £10,918,552 (2023 - £10,744,658)
Gross profit margin: 55.7% (2023 - 55.4%)


Alpha-Cure Group Limited (Registered number: 12267717)

Group Strategic Report
for the Year Ended 31 December 2024

FUTURE OUTLOOK
We anticipate strong demand driven by accelerating adoption and use of our products, through increase use, new technology, new sector uses and market expansion.
This is backed by "UV Curing System Market Forecast to 2028" estimated a compound annual growth rate of 9.0% from 2021 to 2028,

ON BEHALF OF THE BOARD:





M A Slater - Director


30 September 2025

Alpha-Cure Group Limited (Registered number: 12267717)

Report of the Directors
for the Year Ended 31 December 2024

The directors present their report with the financial statements of the company and the group for the year ended 31 December 2024.

PRINCIPAL ACTIVITY
The principal activity of the group in the year under review was that of the manufacture and sale of UV and Metal Halide lamps.

DIVIDENDS
The total distribution of dividends for the year ended 31 December 2024 was £1,793,700.

DIRECTORS
The directors shown below have held office during the whole of the period from 1 January 2024 to the date of this report.

S P Atherstone
S Haines
M A Slater

FINANCIAL INSTRUMENTS
The group uses various financial instruments including cash, trade debtors, and trade creditors that arise
directly from the group's operations.

The existence of these financial instruments exposes the group to a number of financial risks, which are described in more detail below.

The main risks arising from the group's financial instruments are liquidity risk, interest rate risk and credit risk. The
directors review and agree policies for managing each of these risks and they are summarised below:

LIQUIDITY RISK
The group seeks to manage finance risk by ensuring sufficient liquidity is available to meet foreseeable needs and to invest cash assets safely and profitably.

INTEREST RATE RISK
The group finances its operations through a mixture of retained profits and cash balances. Cash is managed to
maximise income from interest while avoiding inherent risk.

CREDIT RISK
The group's principle financial assets are cash and trade debtors.

In order to manage credit risk the directors set limits for customers based on a combination of payment history and third party credit references. Credit limits are reviewed by the credit controller on a regular basis in conjunction with debt ageing and collection history.

STATEMENT OF DIRECTORS' RESPONSIBILITIES
The directors are responsible for preparing the Group Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the group and of the profit or loss of the group for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.


Alpha-Cure Group Limited (Registered number: 12267717)

Report of the Directors
for the Year Ended 31 December 2024

STATEMENT OF DIRECTORS' RESPONSIBILITIES - continued
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's and the group's transactions and disclose with reasonable accuracy at any time the financial position of the company and the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS
So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the group's auditors are unaware, and each director has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the group's auditors are aware of that information.

AUDITORS
The auditors, CED Accountancy Services Limited, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:





M A Slater - Director


30 September 2025

Report of the Independent Auditors to the Members of
Alpha-Cure Group Limited

Opinion
We have audited the financial statements of Alpha-Cure Group Limited (the 'parent company') and its subsidiaries (the 'group') for the year ended 31 December 2024 which comprise the Consolidated Income Statement, Consolidated Other Comprehensive Income, Consolidated Balance Sheet, Company Balance Sheet, Consolidated Statement of Changes in Equity, Company Statement of Changes in Equity, Consolidated Cash Flow Statement and Notes to the Consolidated Cash Flow Statement, Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:
-give a true and fair view of the state of the group's and of the parent company affairs as at 31 December 2024 and of the group's profit for the year then ended;
-have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
-have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information
The directors are responsible for the other information. The other information comprises the information in the Group Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006
In our opinion, based on the work undertaken in the course of the audit:
- the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Group Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Report of the Independent Auditors to the Members of
Alpha-Cure Group Limited


Matters on which we are required to report by exception
In the light of the knowledge and understanding of the group and the parent company and its environment obtained in the course of the audit, we have not identified material misstatements in the Group Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:
- adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of directors
As explained more fully in the Statement of Directors' Responsibilities set out on pages four and five, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the group's and the parent company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the group or the parent company or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Members of
Alpha-Cure Group Limited


Auditors' responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

The engagement partner ensured that the engagement team had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
we identified the laws and regulations applicable to the company through discussions with directors and other management;
we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the company, including the Companies Act 2006, taxation legislation, employment environmental and health and safety legislation;
we assessed the extent of compliance with the laws and regulations identified above;
we communicated identified laws and regulations within the audit team who remained alert to instances of non-compliance.

We assessed the susceptibility of the company's financial statements to material misstatement including obtaining an understanding of how fraud might occur, by;

- making enquiries of management as to whether they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud;
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations; and
-understanding the design of the company's remuneration policies.

To address the risk of fraud through management bias and override of controls, we;

- performed analytical procedures to identify any unusual or unexpected relationships;
- tested journal entries to identify unusual transactions;

In response to the risk of non-compliance with laws and regulations, we designed procedures which included, but were not limited to;

- agreeing financial statement disclosures to underlying supporting documentation;
- enquiring of management as to actual and potential litigation and claims; and
- reviewing correspondence with HMRC and the company's legal advisors.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the directors and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Auditors.

Report of the Independent Auditors to the Members of
Alpha-Cure Group Limited


Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.




Duncan Mitchell FCA (Senior Statutory Auditor)
for and on behalf of CED Accountancy Services Limited
Statutory Auditors
Chartered Accountants
1 Lucas Bridge Business Park
1 Old Greens Norton Road
Towcester
Northamptonshire
NN12 8AX

30 September 2025

Alpha-Cure Group Limited (Registered number: 12267717)

Consolidated Income Statement
for the Year Ended 31 December 2024

31.12.24 31.12.23
Notes £    £    £    £   

TURNOVER 3 10,918,552 10,744,658

Cost of sales 4,834,441 4,789,532
GROSS PROFIT 6,084,111 5,955,126

Distribution costs 874,307 911,779
Administrative expenses 2,836,928 3,013,767
3,711,235 3,925,546
2,372,876 2,029,580

Other operating income 8,139 84,363
OPERATING PROFIT 5 2,381,015 2,113,943

Income from shares in group undertakings - 28,600
Income from interest in associated
undertakings

(6,845

)

(19,050

)
Interest receivable and similar income 1,051 328
(5,794 ) 9,878
2,375,221 2,123,821

Interest payable and similar expenses 6 17,873 62,472
PROFIT BEFORE TAXATION 2,357,348 2,061,349

Tax on profit 7 495,365 234,150
PROFIT FOR THE FINANCIAL YEAR 1,861,983 1,827,199
Profit attributable to:
Owners of the parent 1,971,437 1,909,557
Non-controlling interests (109,454 ) (82,358 )
1,861,983 1,827,199

Alpha-Cure Group Limited (Registered number: 12267717)

Consolidated Other Comprehensive Income
for the Year Ended 31 December 2024

31.12.24 31.12.23
Notes £    £   

PROFIT FOR THE YEAR 1,861,983 1,827,199


OTHER COMPREHENSIVE INCOME
Foreign exchange (50,447 ) (581,499 )
Income tax relating to other comprehensive
income

-

-
OTHER COMPREHENSIVE INCOME
FOR THE YEAR, NET OF INCOME TAX

(50,447

)

(581,499

)
TOTAL COMPREHENSIVE INCOME
FOR THE YEAR

1,811,536

1,245,700

Total comprehensive income attributable to:
Owners of the parent 1,920,991 1,328,058
Non-controlling interests (109,455 ) (82,358 )
1,811,536 1,245,700

Alpha-Cure Group Limited (Registered number: 12267717)

Consolidated Balance Sheet
31 December 2024

31.12.24 31.12.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 922,684 665
Tangible assets 11 3,046,630 3,275,775
Investments 12
Interest in associate 202,198 209,043
Other investments 747 783
4,172,259 3,486,266

CURRENT ASSETS
Stocks 13 3,043,479 2,868,219
Debtors 14 2,661,449 2,217,966
Cash at bank and in hand 1,977,425 2,404,685
7,682,353 7,490,870
CREDITORS
Amounts falling due within one year 15 2,004,612 1,387,997
NET CURRENT ASSETS 5,677,741 6,102,873
TOTAL ASSETS LESS CURRENT
LIABILITIES

9,850,000

9,589,139

CREDITORS
Amounts falling due after more than one
year

16

(320,271

)

(24,019

)

PROVISIONS FOR LIABILITIES 20 (128,966 ) (182,192 )
NET ASSETS 9,400,763 9,382,928

CAPITAL AND RESERVES
Called up share capital 21 6,000 6,000
Retained earnings 22 6,496,740 6,369,450
SHAREHOLDERS' FUNDS 6,502,740 6,375,450

NON-CONTROLLING INTERESTS 2,898,023 3,007,478
TOTAL EQUITY 9,400,763 9,382,928

Alpha-Cure Group Limited (Registered number: 12267717)

Consolidated Balance Sheet - continued
31 December 2024



The financial statements were approved by the Board of Directors and authorised for issue on 30 September 2025 and were signed on its behalf by:





M A Slater - Director


Alpha-Cure Group Limited (Registered number: 12267717)

Company Balance Sheet
31 December 2024

31.12.24 31.12.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 10 - -
Tangible assets 11 - -
Investments 12 6,849,850 6,849,850
6,849,850 6,849,850

CURRENT ASSETS
Debtors 14 4,526,000 4,526,000
NET CURRENT ASSETS 4,526,000 4,526,000
TOTAL ASSETS LESS CURRENT
LIABILITIES

11,375,850

11,375,850

CAPITAL AND RESERVES
Called up share capital 21 6,000 6,000
Other reserves 22 11,369,850 11,369,850
SHAREHOLDERS' FUNDS 11,375,850 11,375,850

Company's profit for the financial year 1,184,400 521,400

Alpha-Cure Group Limited (Registered number: 12267717)

Company Balance Sheet - continued
31 December 2024



The financial statements were approved by the Board of Directors and authorised for issue on 30 September 2025 and were signed on its behalf by:





M A Slater - Director


Alpha-Cure Group Limited (Registered number: 12267717)

Consolidated Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up
share Retained Non-controlling Total
capital earnings Total interests equity
£    £    £    £    £   
Balance at 1 January 2023 6,000 5,869,478 5,875,478 3,089,836 8,965,314

Changes in equity
Dividends - (828,086 ) (828,086 ) - (828,086 )
Total comprehensive income - 1,328,058 1,328,058 (82,358 ) 1,245,700
Balance at 31 December 2023 6,000 6,369,450 6,375,450 3,007,478 9,382,928

Changes in equity
Dividends - (1,793,700 ) (1,793,700 ) - (1,793,700 )
Total comprehensive income - 1,920,990 1,920,990 (109,455 ) 1,811,535
Balance at 31 December 2024 6,000 6,496,740 6,502,740 2,898,023 9,400,763

Alpha-Cure Group Limited (Registered number: 12267717)

Company Statement of Changes in Equity
for the Year Ended 31 December 2024

Called up
share Retained Other Total
capital earnings reserves equity
£    £    £    £   
Balance at 1 January 2023 6,000 - 11,369,850 11,375,850

Changes in equity
Dividends - (521,400 ) - (521,400 )
Total comprehensive income - 521,400 - 521,400
Balance at 31 December 2023 6,000 - 11,369,850 11,375,850

Changes in equity
Dividends - (1,184,400 ) - (1,184,400 )
Total comprehensive income - 1,184,400 - 1,184,400
Balance at 31 December 2024 6,000 - 11,369,850 11,375,850

Alpha-Cure Group Limited (Registered number: 12267717)

Consolidated Cash Flow Statement
for the Year Ended 31 December 2024

31.12.24 31.12.23
Notes £    £   
Cash flows from operating activities
Cash generated from operations 1 2,752,761 2,465,730
Interest paid (13,724 ) (60,324 )
Interest element of hire purchase payments
paid

(2,298

)

(1,182

)
Finance costs paid (1,851 ) (966 )
Tax paid (337,463 ) (529,212 )
Net cash from operating activities 2,397,425 1,874,046

Cash flows from investing activities
Purchase of intangible fixed assets (950,294 ) -
Purchase of tangible fixed assets (335,673 ) (381,377 )
Sale of tangible fixed assets 119,040 38,794
Decrease in investment in associate (6,845 ) 19,050
Interest received 1,051 328
Dividends received - 28,600
Net cash from investing activities (1,172,721 ) (294,605 )

Cash flows from financing activities
New loans in year 390,000 -
Loan repayments in year (32,872 ) (45,000 )
New HP in year 6,845 -
Capital repayments in year (20,443 ) (12,166 )
Amount introduced by directors 228,329 204,441
Amount withdrawn by directors (191,753 ) (504,309 )
Equity dividends paid (1,793,700 ) (828,086 )
Net cash from financing activities (1,413,594 ) (1,185,120 )

(Decrease)/increase in cash and cash equivalents (188,890 ) 394,321
Cash and cash equivalents at beginning of
year

2

2,166,315

1,771,994

Cash and cash equivalents at end of year 2 1,977,425 2,166,315

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Cash Flow Statement
for the Year Ended 31 December 2024

1. RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM
OPERATIONS

31.12.24 31.12.23
£    £   
Profit before taxation 2,357,348 2,061,349
Depreciation charges 426,727 411,785
(Profit)/loss on disposal of fixed assets (41,731 ) 15,287
Foreign exchange 114,992 (321,861 )
Finance costs 17,873 62,472
Finance income 5,794 (9,878 )
2,881,003 2,219,154
(Increase)/decrease in stocks (175,260 ) 305,121
(Increase)/decrease in trade and other debtors (499,913 ) 81,342
Increase/(decrease) in trade and other creditors 546,931 (139,887 )
Cash generated from operations 2,752,761 2,465,730

2. CASH AND CASH EQUIVALENTS

The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

Year ended 31 December 2024
31.12.24 1.1.24
£    £   
Cash and cash equivalents 1,977,425 2,404,685
Bank overdrafts - (238,370 )
1,977,425 2,166,315
Year ended 31 December 2023
31.12.23 1.1.23
£    £   
Cash and cash equivalents 2,404,685 1,771,994
Bank overdrafts (238,370 ) -
2,166,315 1,771,994


Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Cash Flow Statement
for the Year Ended 31 December 2024

3. ANALYSIS OF CHANGES IN NET FUNDS

Other
non-cash
At 1.1.24 Cash flow changes At 31.12.24
£    £    £    £   
Net cash
Cash at bank
and in hand 2,404,685 (427,260 ) 1,977,425
Bank overdrafts (238,370 ) 238,370 -
2,166,315 (188,890 ) 1,977,425
Debt
Finance leases (41,093 ) 11,301 (58,708 ) (88,500 )
Debts falling due
within 1 year - (97,500 ) - (97,500 )
Debts falling due
after 1 year - (268,125 ) - (268,125 )
(41,093 ) (354,324 ) (58,708 ) (454,125 )
Total 2,125,222 (543,214 ) (58,708 ) 1,523,300

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Alpha-Cure Group Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the General Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Basis of consolidation
The Group and all its subsidiary undertakings, except where the subsidiary is immaterial to the group in size and or function, are consolidated. Intercompany transactions and balances among Group companies are eliminated in full. The Group's share of results from associates are accounted for using equity accounting principles. The results and fair values of the assets and liabilities of undertakings acquired are consolidated from the date on which the Group gains control. The results from discontinued operations are included up until the date on which they are disposed of or terminated. Where, in the view of the directors, the Group does not have de facto control over the related entities, these entities are excluded from the consolidation in the Group's financial statements. Business combinations are accounted for using the purchase method of accounting under FRS 102, Section 19 Business Combinations. In the balance sheet, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at fair value at the date of acquisition (which is the date on which control is passed to the parent). The results of the acquired operations are included in the consolidated profit and loss account from the date of acquisition. Consolidation ceases from the date on which control ceases.

Related party exemption
The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Transactions between group entities which have been eliminated on consolidation are not disclosed within the financial statements.

Significant judgements and estimates
In the application of the company's accounting policies management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover comprises the fair value of the consideration received or receivable for the sale of lamps and lighting components to customers in the ordinary course of the group's activities.

Turnover is shown net of value added tax, returns, rebates and discounts.

The group recognises revenue when:

The amount of revenue can be reliably measured;

it is probable that future economic benefits will flow to the entity:

and specific criteria have been met for each of the group's activities.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2024, is being amortised evenly over its estimated useful life of ten years.

In September 2024, the company purchased production line assets from USA for $1,500,000. This product line manufactures pressure lamps which incorporate UV technology. Goodwill on purchase was valued at £928,619 and is being written off over its estimated useful life of 10 years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of ten years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.
Freehold property - 4.75% on cost and 1% on cost
Short leasehold - 15% on cost
Plant and machinery - 15% on reducing balance
Fixtures and fittings - 25% on reducing balance
Motor vehicles - 25% on cost
Computer equipment - 25% on reducing balance

Investments in associates
Investments in associate undertakings are recognised at cost.

Stocks
Stocks and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, bank overdrafts, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other
accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest rate method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in a case of an out-right short term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Income Statement.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate of the recoverable amount, which is an approximation of the amount that the Company would receive if the asset were to be sold at the reporting date.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Consolidated Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development
Expenditure on research and development is written off in the year in which it is incurred.


Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Foreign currencies
Functional and presentation currency
The Group’s financial statements are presented in Sterling (£) and rounded to thousands (unless stated otherwise). The individual financial statements of each Group entity are prepared in the currency of the primary economic environment in which the entity operates (its functional currency). These financial statements are then translated into the Group’s presentation currency for consolidation purposes as described below.

The Company’s functional and presentational currency is Sterling.

Transactions and balances
In preparing the financial statements of the individual entities, transactions in currencies other than the functional currency of the individual entities (foreign currencies) are recognised at the spot rate at the dates of the transactions, or at an average rate where this rate approximates the actual rate at the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Nonmonetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.


Exchange differences are recognised in profit or loss in the period in which they arise. However, in the consolidated financial statements exchange differences arising on monetary items that form part of the net investment in a foreign operation are recognised in other comprehensive income and are not reclassified to profit or loss.

Translation of group companies
For the purpose of presenting consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated from their functional currency to Sterling using the closing exchange rate. Income and expenses are translated using the average rate for the period, unless exchange rates fluctuated significantly during that period, in which case the exchange rates at the dates of the transactions are used.

Exchange differences arising on the translation of group companies are recognised in other comprehensive income. If the Group disposes of the foreign operation the cumulative exchange difference is not reclassified to profit or loss but is transferred within equity to retained earnings.

Goodwill and fair value adjustments arising on the acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the closing rate.

Hire purchase and leasing commitments
Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

Pension costs and other post-retirement benefits
The group operates a defined contribution pension scheme. Contributions payable to the group's pension scheme are charged to profit or loss in the period to which they relate.

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

3. TURNOVER

The turnover and profit before taxation are attributable to the one principal activity of the group.

An analysis of turnover by geographical market is given below:

31.12.24 31.12.23
£    £   
United Kingdom 4,600,880 4,271,442
Europe 1,957,706 1,860,326
Rest of the World 4,359,966 4,612,890
10,918,552 10,744,658

4. EMPLOYEES AND DIRECTORS
31.12.24 31.12.23
£    £   
Wages and salaries 2,557,717 3,065,177
Social security costs 169,070 208,238
Other pension costs 113,164 81,463
2,839,951 3,354,878

The average number of employees during the year was as follows:
31.12.24 31.12.23

Manufacturing 67 72
Sales and administration 42 48
109 120

The average number of employees by undertakings that were proportionately consolidated during the year was 109 (2023 - 120 ) .

31.12.24 31.12.23
£    £   
Directors' remuneration 211,139 195,536
Directors' pension contributions to money purchase schemes 60,437 14,302

The number of directors to whom retirement benefits were accruing was as follows:

Money purchase schemes 3 3

Information regarding the highest paid director for the year ended 31 December 2024 is as follows:
31.12.24
£   
Emoluments etc 73,433
Pension contributions to money purchase schemes 14,000

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

5. OPERATING PROFIT

The operating profit is stated after charging/(crediting):

31.12.24 31.12.23
£    £   
Depreciation - owned assets 418,299 413,824
Depreciation - assets on hire purchase contracts 11,322 3,774
(Profit)/loss on disposal of fixed assets (41,731 ) 15,287
Goodwill amortisation 27,085 -
Patents and licences amortisation 1,190 288
Auditors' remuneration 6,820 5,000
Auditors' remuneration for non audit work 13,104 13,104

6. INTEREST PAYABLE AND SIMILAR EXPENSES
31.12.24 31.12.23
£    £   
Bank interest 13,413 38,750
Pension loan interest - 7,803
HMRC interest 311 13,771
Hire purchase 2,298 1,182
Fines and penalties 1,851 966
17,873 62,472

7. TAXATION

Analysis of the tax charge
The tax charge on the profit for the year was as follows:
31.12.24 31.12.23
£    £   
Current tax:
UK corporation tax 542,247 224,567
Prior year over/underprovision 6,344 (15,548 )
Total current tax 548,591 209,019

Deferred tax (53,226 ) 25,131
Tax on profit 495,365 234,150

UK corporation tax has been charged at 25 % (2023 - 23.50 %).

Tax effects relating to effects of other comprehensive income

31.12.24
Gross Tax Net
£    £    £   
Foreign exchange (50,447 ) - (50,447 )


Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

7. TAXATION - continued
31.12.23
Gross Tax Net
£    £    £   
Foreign exchange (581,499 ) - (581,499 )

8. INDIVIDUAL INCOME STATEMENT

As permitted by Section 408 of the Companies Act 2006, the Income Statement of the parent company is not presented as part of these financial statements.


9. DIVIDENDS
31.12.24 31.12.23
£    £   
Ordinary shares of £1 each
Interim 1,793,700 828,086

10. INTANGIBLE FIXED ASSETS

Group
Patents
and
Goodwill licences Totals
£    £    £   
COST
At 1 January 2024 - 5,727 5,727
Additions 928,619 21,675 950,294
At 31 December 2024 928,619 27,402 956,021
AMORTISATION
At 1 January 2024 - 5,062 5,062
Amortisation for year 27,085 1,190 28,275
At 31 December 2024 27,085 6,252 33,337
NET BOOK VALUE
At 31 December 2024 901,534 21,150 922,684
At 31 December 2023 - 665 665

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

11. TANGIBLE FIXED ASSETS

Group
Freehold Short Plant and
property leasehold machinery
£    £    £   
COST
At 1 January 2024 2,580,344 227,411 4,024,202
Additions - - 279,875
Disposals (674 ) - (147,141 )
Exchange differences (29,108 ) - (16,274 )
Transfer to ownership - - (79,438 )
At 31 December 2024 2,550,562 227,411 4,061,224
DEPRECIATION
At 1 January 2024 440,297 122,951 3,309,429
Charge for year 111,957 19,202 206,097
Eliminated on disposal - - (90,198 )
Exchange differences (4,967 ) - (5,412 )
At 31 December 2024 547,287 142,153 3,419,916
NET BOOK VALUE
At 31 December 2024 2,003,275 85,258 641,308
At 31 December 2023 2,140,047 104,460 714,773

Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
COST
At 1 January 2024 1,111,982 157,442 3,689 8,105,070
Additions 92,812 20,869 825 394,381
Disposals - (22,346 ) - (170,161 )
Exchange differences (2,482 ) (2,113 ) (172 ) (50,149 )
Transfer to ownership - - - (79,438 )
At 31 December 2024 1,202,312 153,852 4,342 8,199,703
DEPRECIATION
At 1 January 2024 910,261 43,616 2,741 4,829,295
Charge for year 60,603 30,162 1,600 429,621
Eliminated on disposal - (2,654 ) - (92,852 )
Exchange differences (1,187 ) (1,297 ) (128 ) (12,991 )
At 31 December 2024 969,677 69,827 4,213 5,153,073
NET BOOK VALUE
At 31 December 2024 232,635 84,025 129 3,046,630
At 31 December 2023 201,721 113,826 948 3,275,775

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

11. TANGIBLE FIXED ASSETS - continued

Group

Fixed assets, included in the above, which are held under hire purchase contracts are as follows:
Fixtures
and Motor
fittings vehicles Totals
£    £    £   
COST
At 1 January 2024 - 45,289 45,289
Additions 58,708 - 58,708
At 31 December 2024 58,708 45,289 103,997
DEPRECIATION
At 1 January 2024 - 3,774 3,774
Charge for year - 11,322 11,322
At 31 December 2024 - 15,096 15,096
NET BOOK VALUE
At 31 December 2024 58,708 30,193 88,901
At 31 December 2023 - 41,515 41,515

12. FIXED ASSET INVESTMENTS

Group
Interest
in Listed
associate investments Totals
£    £    £   
COST
At 1 January 2024 209,043 783 209,826
Share of profit/(loss) (6,845 ) - (6,845 )
Exchange differences - (36 ) (36 )
At 31 December 2024 202,198 747 202,945
NET BOOK VALUE
At 31 December 2024 202,198 747 202,945
At 31 December 2023 209,043 783 209,826

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

12. FIXED ASSET INVESTMENTS - continued

Company
Shares in
group
undertakings
£   
COST
At 1 January 2024
and 31 December 2024 6,849,850
NET BOOK VALUE
At 31 December 2024 6,849,850
At 31 December 2023 6,849,850

The group or the company's investments at the Balance Sheet date in the share capital of companies include the following:

Subsidiaries

Alpha-Cure Limited
Registered office: Leonard House, Great Central Way, Woodford Halse, Daventry, Northamptonshire, NN11 3PZ
Nature of business: Manufacture and sale of UV and Metal Halide lamps
%
Class of shares: holding
Ordinary 75.00
31.12.24 31.12.23
£    £   
Aggregate capital and reserves 4,918,015 4,338,549
Profit for the year 2,121,366 1,378,499

Alpha-Cure Asia Limited
Registered office: Room 1805, No.481-485 HuaQing South road, QingPu District, 201700 Shanghai City, China
Nature of business: Manufacture and sale of UV and Metal Halide lamps
%
Class of shares: holding
Ordinary 56.25
31.12.24 31.12.23
£    £   
Aggregate capital and reserves 5,124,385 5,520,441
Profit for the year 441,213 742,931

Alpha-Cure Asia Limited is a 75% subsidiary of Alpha-Cure Holdings Limited, which is a 100% subsidiary of Alpha-Cure Limited, which is a 75% subsidiary of Alpha-Cure Group Limited.

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

12. FIXED ASSET INVESTMENTS - continued

Alpha-Cure Deutschland GmbH
Registered office: Von-Siemens-Straße 5,48346 Ostbevern, Deutschland, 48165 Ostbevern, Germany
Nature of business: Sale of UV and Metal Halide lamps
%
Class of shares: holding
Ordinary 75.00
31.12.24 31.12.23
£    £   
Aggregate capital and reserves 340,724 350,498
Profit for the year 6,160 14,677

Alpha-Cure (Jiangsu) Co. LTD
Registered office: 1360 Nanyuan West Road, Qidong Economic Development Zone, Qidong City, Jiangsu Province 226200, China
Nature of business: Manufacture and sale of UV and Metal Halide lamps
%
Class of shares: holding
Ordinary 56.25
31.12.24 31.12.23
£    £   
Aggregate capital and reserves 5,364,020 5,479,034
Profit for the year 240,703 532,263

Alpha-Cure (Jiangsu) Co. LTD is a 100% subsidiary of Alpha-Cure Asia Limited, which is a 75% subsidiary of Alpha-Cure Holdings Limited, which is a 100% subsidiary of Alpha-Cure Limited, which is a 75% subsidiary of Alpha-Cure Group Limited.

Alpha Cure Australia PTY LTD
Registered office: 27 Ashburton Avenue, West Lakes Shore, SA 5020 Australia.
Nature of business: Sale of UV and Metal Halide lamps
%
Class of shares: holding
Ordinary 75.00
30.6.24 30.6.23
£    £   
Aggregate capital and reserves 7,496 12,691
(Loss)/profit for the year (5,142 ) 680

Alpha Cure Australia PTY LTD is excluded from consolidation as it is not material to the group, in size or function.

Alpha-Cure Holdings Limited
Registered office: Leonard House Unit 2 Great Central Way, Woodford Halse, Daventry, England, NN11 3PZ
Nature of business: Holding Company
%
Class of shares: holding
Ordinary 75.00
31.12.24 31.12.23
£    £   
Aggregate capital and reserves 520,358 505,821
Profit for the year 537,506 405,533

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

12. FIXED ASSET INVESTMENTS - continued

Associated company

Alpha-Cure France Sarl
Registered office: ZA DE LA GARE, 9 Rue des Fontaines, 37310 Reignac-sur-Indre, France
Nature of business: Sale of UV and Metal Halide lamps
%
Class of shares: holding
Ordinary 36.25
31.12.24 31.12.23
£    £   
Aggregate capital and reserves 412,649 426,619
Profit for the year 35,060 32,255


13. STOCKS

Group
31.12.24 31.12.23
£    £   
Raw materials 1,526,860 1,405,453
Work-in-progress 52,495 65,135
Finished goods 1,088,466 1,169,717
Goods in transit 375,658 227,914
3,043,479 2,868,219

14. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group Company
31.12.24 31.12.23 31.12.24 31.12.23
£    £    £    £   
Trade debtors 1,984,643 1,892,010 - -
Amounts owed by group undertakings - - 4,526,000 4,526,000
Other debtors 546,505 144,337 - -
Directors' current accounts 79,651 116,245 - -
Tax 6,434 26,270 - -
Prepayments 44,216 39,104 - -
2,661,449 2,217,966 4,526,000 4,526,000

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

15. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

Group
31.12.24 31.12.23
£    £   
Bank loans and overdrafts (see note 17) 97,500 238,370
Hire purchase contracts (see note 18) 36,354 17,074
Trade creditors 421,942 346,563
Tax 392,967 201,675
Social security and other taxes 45,587 48,228
VAT 207,109 261,523
Other creditors 736,067 171,250
Directors' current accounts 10,243 10,261
Accrued expenses 56,843 93,053
2,004,612 1,387,997

16. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR

Group
31.12.24 31.12.23
£    £   
Bank loans (see note 17) 268,125 -
Hire purchase contracts (see note 18) 52,146 24,019
320,271 24,019

17. LOANS

An analysis of the maturity of loans is given below:

Group
31.12.24 31.12.23
£    £   
Amounts falling due within one year or on demand:
Bank overdrafts - 238,370
Bank loans 97,500 -
97,500 238,370
Amounts falling due between one and two years:
Bank loans - 1-2 years 97,500 -
Amounts falling due between two and five years:
Bank loans - 2-5 years 170,625 -

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

18. LEASING AGREEMENTS

Minimum lease payments fall due as follows:

Group
Hire purchase
contracts
31.12.24 31.12.23
£    £   
Net obligations repayable:
Within one year 36,354 17,074
Between one and five years 52,146 24,019
88,500 41,093

Group
Non-cancellable
operating leases
31.12.24 31.12.23
£    £   
Within one year 123,350 133,638
Between one and five years 7,296 107,064
130,646 240,702

19. SECURED DEBTS

The following secured debts are included within creditors:

Group
31.12.24 31.12.23
£    £   
Bank loans 365,625 -
Hire purchase contracts 88,500 -
454,125 -

Included within the Group's creditors are bank loans upon which National Westminster Bank Plc hold debentures dated 2 January 2007 and 8 May 2008 including a first fixed charge on book debts and other debts.

All finance lease and hire purchase contracts are secured on assets financed (see note 6).

20. PROVISIONS FOR LIABILITIES

Group
31.12.24 31.12.23
£    £   
Deferred tax 128,966 182,192

Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

20. PROVISIONS FOR LIABILITIES - continued

Group
Deferred
tax
£   
Balance at 1 January 2024 182,192
Credit to Income Statement during year (17,720 )
Accelerated capital allowances (35,506 )
Change in tax rate
Balance at 31 December 2024 128,966

21. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.12.24 31.12.23
value: £    £   
6,000 Ordinary £1 6,000 6,000

22. RESERVES

Group
Retained
earnings
£   

At 1 January 2024 6,369,450
Profit for the year 1,971,437
Dividends (1,793,700 )
Foreign exchange (50,447 )
At 31 December 2024 6,496,740

Company
Retained Other
earnings reserves Totals
£    £    £   

At 1 January 2024 - 11,369,850 11,369,850
Profit for the year 1,184,400 1,184,400
Dividends (1,184,400 ) (1,184,400 )
At 31 December 2024 - 11,369,850 11,369,850


Alpha-Cure Group Limited (Registered number: 12267717)

Notes to the Consolidated Financial Statements - continued
for the Year Ended 31 December 2024

23. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31 December 2024 and 31 December 2023:

31.12.24 31.12.23
£    £   
S P Atherstone
Balance outstanding at start of year 26,145 26,196
Amounts advanced 2,037 -
Amounts repaid (2,507 ) (51 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 25,675 26,145

S Haines
Balance outstanding at start of year 60,532 1,585
Amounts advanced 1,796 60,000
Amounts repaid (61,154 ) (1,053 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 1,174 60,532

M A Slater
Balance outstanding at start of year 29,568 (85,547 )
Amounts advanced 187,901 120,000
Amounts repaid (164,667 ) (4,885 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 52,802 29,568

Loans to the directors are provided with an interest charge at 0% and are repayable on demand.